Lucid Diagnostics Inc. LUCD 深 滬
等待開盤 05-20 09:30:00 美东时间
0.947
-0.008
-0.85%
華盛通- 最 高1.01
- 今 開0.96
- 成交量 70.46万股
- 最 低 0.9424
- 昨 收 0.9551
- 總市值 1.92亿
- 52周最高 1.6293
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 0.9424
- 委 比 -17.65%
- 總股本 2.03亿
- 歷史最高 13.52
- 量 比 0.56
- 振 幅 7.08%
- 歷史最低 0.6301
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
05-15 19:37
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Lucid Diagnostics Q1 Sales $1.256M Miss $1.383M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst consensus estimate of $1.383 million by 9.18 percent. This is a 57.00 percent increase over sales of $800.000 thousand
05-14 18:02
Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an
04-23 20:36
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Texas Instruments To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stanley raised AA target, Ascendiant raised LUCD.
04-09 22:13
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8.25 to $9.
04-09 18:39
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophagea...
04-02 20:01
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
